{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Vaccine+2&page=8",
    "query": {
      "intervention": "Control Vaccine 2",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 680,
    "total_pages": 68,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Vaccine+2&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Vaccine+2&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T05:51:56.188Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05901636",
      "title": "A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza Prevention"
      ],
      "interventions": [
        {
          "name": "INFLUENZA G1 mHA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Al(OH)3",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Janssen Vaccines & Prevention B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 170,
      "start_date": "2023-05-17",
      "completion_date": "2024-08-19",
      "has_results": true,
      "last_update_posted_date": "2025-09-08",
      "last_synced_at": "2026-10-17T05:51:56.188Z",
      "location_count": 4,
      "location_summary": "Miami Lakes, Florida • Lenexa, Kansas • Metairie, Louisiana + 1 more",
      "locations": [
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Metairie",
          "state": "Louisiana"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05901636"
    },
    {
      "nct_id": "NCT00001019",
      "title": "Safety of and Immune Response to an HIV Vaccine (SF-2 gp120) With or Without MTP-PE/MF59 Adjuvant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "rgp120/HIV-1 SF-2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MTP-PE/MF59",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 48,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2012-10-30",
      "last_synced_at": "2026-10-17T05:51:56.188Z",
      "location_count": 4,
      "location_summary": "St Louis, Missouri • Philadelphia, Pennsylvania • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001019"
    },
    {
      "nct_id": "NCT01266616",
      "title": "Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Profectus HIV MAG pDNA vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IL-12",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 62,
      "start_date": "2011-03",
      "completion_date": "2013-04",
      "has_results": false,
      "last_update_posted_date": "2021-11-01",
      "last_synced_at": "2026-10-17T05:51:56.188Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Palo Alto, California • San Francisco, California + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01266616"
    },
    {
      "nct_id": "NCT06036134",
      "title": "Reducing COVID-19 Vaccine Hesitancy Among Hispanic Parents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Vaccine-Preventable Diseases",
        "COVID-19 Pandemic",
        "Health-Related Behavior",
        "Health Knowledge, Attitudes, Practice",
        "Narration"
      ],
      "interventions": [
        {
          "name": "Baseline surveys",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Digital Storytelling Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Information Control Intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Arizona State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2023-12-01",
      "completion_date": "2025-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-26",
      "last_synced_at": "2026-10-17T05:51:56.188Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06036134"
    },
    {
      "nct_id": "NCT05457959",
      "title": "Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diffuse Hemispheric Glioma, H3 G34-Mutant"
      ],
      "interventions": [
        {
          "name": "Dendritic Cell Tumor Peptide Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Leukapheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo Administration",
          "type": "DRUG"
        },
        {
          "name": "Poly ICLC",
          "type": "DRUG"
        },
        {
          "name": "Resection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "13 Years to 60 Years"
      },
      "enrollment_count": 0,
      "start_date": "2024-12-01",
      "completion_date": "2030-12-01",
      "has_results": false,
      "last_update_posted_date": "2025-02-24",
      "last_synced_at": "2026-10-17T05:51:56.188Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05457959"
    },
    {
      "nct_id": "NCT00006291",
      "title": "Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "ALVAC(2)120(B,MN)GNP (vCP1452)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aldesleukin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": null,
      "completion_date": "2005-10",
      "has_results": false,
      "last_update_posted_date": "2021-11-01",
      "last_synced_at": "2026-10-17T05:51:56.188Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 18 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006291"
    },
    {
      "nct_id": "NCT00409188",
      "title": "Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Tecemotide (L-BLP25)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Single low dose cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "EMD Serono",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1513,
      "start_date": "2007-01",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2015-11-20",
      "last_synced_at": "2026-10-17T05:51:56.188Z",
      "location_count": 49,
      "location_summary": "Fort Smith, Arkansas • Anaheim, California • Glendale, California + 41 more",
      "locations": [
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00409188"
    },
    {
      "nct_id": "NCT06634797",
      "title": "A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "mRNA-1273.712",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "12 Years to 30 Years"
      },
      "enrollment_count": 1000,
      "start_date": "2024-10-08",
      "completion_date": "2025-01-20",
      "has_results": true,
      "last_update_posted_date": "2026-02-04",
      "last_synced_at": "2026-10-17T05:51:56.188Z",
      "location_count": 24,
      "location_summary": "Phoenix, Arizona • Huntington Park, California • La Mesa, California + 21 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "San Bernardino",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06634797"
    },
    {
      "nct_id": "NCT00000822",
      "title": "A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Ritonavir",
          "type": "DRUG"
        },
        {
          "name": "gp160 Vaccine (Immuno-AG)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Stavudine",
          "type": "DRUG"
        },
        {
          "name": "Didanosine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 46,
      "start_date": null,
      "completion_date": "1999-05",
      "has_results": false,
      "last_update_posted_date": "2021-10-29",
      "last_synced_at": "2026-10-17T05:51:56.188Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000822"
    },
    {
      "nct_id": "NCT00686075",
      "title": "A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "MEDI-534, Cohort 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo, Cohort 1",
          "type": "OTHER"
        },
        {
          "name": "MEDI-534, Cohort 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo, Cohort 2",
          "type": "OTHER"
        },
        {
          "name": "MEDI-534, Cohort 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo, Cohort 3",
          "type": "OTHER"
        },
        {
          "name": "MEDI-534, Cohort 4",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo, Cohort 4",
          "type": "OTHER"
        },
        {
          "name": "MEDI-534, Cohort 5",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo, Cohort 5",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "23 Months",
        "sex": "ALL",
        "summary": "2 Months to 23 Months"
      },
      "enrollment_count": 1338,
      "start_date": "2008-06",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2014-09-26",
      "last_synced_at": "2026-10-17T05:51:56.188Z",
      "location_count": 51,
      "location_summary": "Mobile, Alabama • Bentonville, Arkansas • Little Rock, Arkansas + 44 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Bentonville",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00686075"
    }
  ]
}